NASDAQ:RZLT

Rezolute (RZLT) Stock Forecast, Price & News

$1.37

+0.04 (+3.01%)

(As of 12:32 PM ET)

Compare

Today's Range: $1.33
▼
$1.43
50-Day Range: $1.33
▼
$2.04
52-Week Range: $1.30
▼
$2.97

Volume: 35,066 shs
Average Volume: 30,408 shs
Market Capitalization: $50.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Rezolute MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 529.4% Upside
$9.00 Price Target
Short Interest: Bearish
0.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.68
Based on 12 Articles This Week
Insider Trading: Acquiring Shares
$9,500 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.17) to ($1.11) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

344th out of 961 stocks

Pharmaceutical Preparations Industry

147th out of 454 stocks

3.5

Analyst's Opinion

Consensus Rating
Rezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Rezolute has a forecasted upside of 529.4% from its current price of $1.43.
Amount of Analyst Coverage
Rezolute has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.94% of the outstanding shares of Rezolute have been sold short.
Short Interest Ratio / Days to Cover
Rezolute has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Rezolute has recently increased by 0.49%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rezolute does not currently pay a dividend.
Dividend Growth
Rezolute does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RZLT.

2.6

News and Social Media Coverage

News Sentiment
Rezolute has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Rezolute this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
18.20% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.79% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Rezolute are expected to grow in the coming year, from ($1.17) to ($1.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rezolute is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rezolute is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rezolute has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rezolute (NASDAQ:RZLT) Stock

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

RZLT Price History

30 days | 90 days | 365 days | Advanced Chart

RZLT Stock News Headlines

September 23, 2023 | americanbankingnews.com

Cantor Fitzgerald Comments on Rezolute, Inc.'s FY2024 Earnings (NASDAQ:RZLT)

September 21, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for Rezolute, Inc.'s Q1 2024 Earnings (NASDAQ:RZLT)

September 26, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 20, 2023 | americanbankingnews.com

Rezolute (NASDAQ:RZLT) Given Overweight Rating at Cantor Fitzgerald

September 20, 2023 | americanbankingnews.com

Rezolute, Inc. (NASDAQ:RZLT) Expected to Earn Q1 2025 Earnings of ($0.30) Per Share

September 19, 2023 | americanbankingnews.com

Rezolute's (RZLT) Buy Rating Reiterated at HC Wainwright

September 18, 2023 | markets.businessinsider.com

Expert Ratings for Rezolute

September 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT), TG Therapeutics (TGTX) and Harpoon Therapeutics (HARP)

September 26, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 17, 2023 | americanbankingnews.com

Rezolute's (RZLT) Market Outperform Rating Reiterated at JMP Securities

September 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Iovance Biotherapeutics (IOVA)

September 14, 2023 | finance.yahoo.com

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

August 22, 2023 | finance.yahoo.com

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

July 6, 2023 | msn.com

Rezolute (RZLT) Price Target Decreased by 27.78% to 7.96

June 29, 2023 | msn.com

Cantor Fitzgerald Maintains Rezolute (RZLT) Overweight Recommendation

June 29, 2023 | msn.com

HC Wainwright & Co. Reiterates Rezolute (RZLT) Buy Recommendation

June 28, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Rezolute

June 28, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Rezolute (RZLT)

June 27, 2023 | finance.yahoo.com

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

June 20, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on Rezolute (RZLT)

May 22, 2023 | benzinga.com

Rezolute Stock (NASDAQ:RZLT), Insider Trading Activity

May 15, 2023 | msn.com

HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation

May 12, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Rezolute (RZLT)

March 23, 2023 | finance.yahoo.com

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

March 8, 2023 | finance.yahoo.com

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

December 15, 2022 | finance.yahoo.com

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

November 9, 2022 | finance.yahoo.com

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

See More Headlines

Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

RZLT Company Calendar

Last Earnings: 9/14/2023
Today: 9/26/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RZLT
CUSIP: N/A
CIK: 1509261
Web: www.rezolutebio.com
Phone: (650) 206-4507
Fax: N/A
Employees: 47
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +576.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.51%
Return on Assets: -36.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.17
Quick Ratio: 20.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.15 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 36,830,000
Free Float: 30,125,000
Market Cap: $48.98 million
Optionable: Not Optionable
Beta: 2.16

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Nevan Charles Elam J.D. (Age 56)
Founder, CEO & Acting Chairman
Comp: $918.34k

Dr. Brian Kenneth Roberts M.D. (Age 48)
Chief Medical Officer
Comp: $575.43k

Mr. Chris Milks
VP & Head of Fin.

Dr. Davelyn Eaves Hood M.B.A.
M.D., Director and Head of Scientific & Patient Affairs

Mr. Michael R. Deperro
Sr. VP & Head of Corp. Devel.

Mr. Michael Covarrubias
Sr. VP & Head of Program & Portfolio Management

Dr. Raj Agrawal M.D.
VP & Head of Ophthalmological Clinical Devel.

Ms. Robyn Sweinhart
VP & Head of Quality

Ms. Erin O'Boyle
Sr. VP & Head of Clinical Operations

Ms. Susan Stewart J.D. (Age 62)
L.L.M., Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RZLT Stock - Frequently Asked Questions

Should I buy or sell Rezolute stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RZLT shares.
View RZLT analyst ratings or view top-rated stocks.
What is Rezolute's stock price forecast for 2023?: 3 brokers have issued 12-month price targets for Rezolute's shares. Their RZLT share price forecasts range from $5.00 to $14.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 576.7% from the stock's current price.
View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts.
How have RZLT shares performed in 2023?: Rezolute's stock was trading at $2.07 at the beginning of 2023. Since then, RZLT shares have decreased by 35.7% and is now trading at $1.33.
View the best growth stocks for 2023 here.
When is Rezolute's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our RZLT earnings forecast.
How were Rezolute's earnings last quarter?: Rezolute, Inc. (NASDAQ:RZLT) announced its quarterly earnings data on Thursday, September, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.11.
What other stocks do shareholders of Rezolute own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO).

What is Rezolute's stock symbol?: Rezolute trades on the NASDAQ under the ticker symbol "RZLT."
Who are Rezolute's major shareholders?: Rezolute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.34%), Stonepine Capital Management LLC (8.34%), Caxton Corp (3.58%), Silverarc Capital Management LLC (1.36%), Citadel Advisors LLC (0.89%) and Northern Trust Corp (0.23%). Insiders that own company stock include Brian Kenneth Roberts, Genexine Inc and Gil M Labrucherie.
View institutional ownership trends.
How do I buy shares of Rezolute?: Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rezolute's stock price today?: One share of RZLT stock can currently be purchased for approximately $1.33.
How much money does Rezolute make?: Rezolute (NASDAQ:RZLT) has a market capitalization of $48.98 million. The company earns $-51,790,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
How can I contact Rezolute?: Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The official website for the company is www.rezolutebio.com. The company can be reached via phone at (650) 206-4507 or via email at investor-relations@rezolutebio.com.

This page (NASDAQ:RZLT) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial